Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imilecleucel-T

- PMLiVE

Sanofi posts positive data for MS drug Aubagio

Phase III study shows drug slows brain volume loss

- PMLiVE

Merck takes novel immuno-oncology drug into clinical trials

Potential to offer alternative to anti-PD-1/anti-PDL1 immunotherapies 

Roche Basel Switzerland

Roche’s investigational drug first to show efficacy in MS

Ocrelizumab shows positive results in large phase III study

- PMLiVE

Merck KGaA appoints Isabel De Paoli as communications head

She will replace Walter Huber, who retires inMarch 2016

Celgene building

Celgene spends $7.2bn on Receptos purchase

Latest deal forms part of a major spending spree for the firm

- PMLiVE

A bright future for OTC and Merck Consumer Health

It’s an exciting time for the OTC sector. Consumers have never been more interested in wellbeing and, of course, avoiding illness. This is driving change, and quickly. The market is...

- PMLiVE

2015 set to be a transitional year for Merck KGaA’s health unit

Weak pharma sales reported by the firm today

- PMLiVE

Genzyme and Ablynx collaborate on multiple sclerosis research

Companies will investigate Nanobodies against MS target

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

Harnessing the power of genetics

In oncology, and other therapy areas, personalised medicines offer new hope against chronic illnesses

- PMLiVE

Merck Serono signs agreement to develop antimalarial therapy

Deal means the German firm obtains rights to candidate DDD107498

- PMLiVE

Nurturing innovation in a tough environment

Much has been achieved in the UK in recent years, but the NHS still has a way to go

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links